Sign In
Aaron Levie Alain de Botton Alan Watts Alexis Ohanian Andreas Antonopoulos Andrew DeSantis Andrew Lo Arthur De Vany Aubrey de Grey Balaji Srinivasan Ben Bratton Bill Bryson Bryan Caplan Carl Jung Chamath Palihapitiya Chris Arnade Chris Sacca Daniel Dennett Daniel Kahneman David Linden David Sacks Derek Parfit Derek Sivers Douglas Hofstadter E.O. Wilson Elon Musk Eric Weinstein Ezra Klein Gad Saad George Gilder George Lakoff Ido Portal J.D. Vance James Altucher James Gleick Jason Silva Jeff Bezos Jim Simons Jocko Willink John Hagelin John Nash Jordan Peterson Josh Waitzkin Julia Galef Kelly Starrett Kevin Kelly Kevin Rose Kim Scott Kumar Thangudu Leonard Shlain Malcolm Gladwell Marc Andreessen Maria Konnikova Maria Popova Matt Ridley Michael Hiltzik Michael Sandel Naval Ravikant Neil Strauss Neil Turok Nick Bostrom Nick Szabo Noah Kagan Noam Chomsky Oliver Sacks P.D. Mangan Paul Bloom Paul Graham Peter Attia Peter Diamandis Peter Thiel Reid Hoffman Rhonda Patrick Richard Feynman Richard Rorty Robert Caro Robert Cialdini Robert Greene Robert Kurzban Robert Langer Robert McNamara Robert Putnam Robert Sapolsky Rory Sutherland Ryan Holiday Sam Altman Sam Harris Scott Adams Scott Belsky Scott Galloway Seth Godin Shawn Baker Shinzen Young Siddhartha Mukherjee Simon Sinek Slavoj Zizek Stephen Wolfram Steve Jobs Steven Pinker Stewart Butterfield Ted Nelson Tiago Forte Tim Ferriss Tim Urban Timothy Gowers Timothy Pychyl Tyler Cowen Vaclav Smil Valter Longo Venkatesh Rao Vinay Gupta Vincent Dignan Will MacAskill Wim Hof Yanis Varoufakis Yuval Harari
Medicine
RELATED THINKERS
Siddhartha Mukherjee Andrew Lo
Siddhartha Mukherjee: On The Cancer Puzzle
21 minutes
MY LIST
Siddhartha Mukherjee's fascination with cancer is rooted not just in how to fight it, but in where it originated. Discovering almost nothing on the subject, the cancer physician and researcher wrote "Emperor of All Maladies: A Biography of Cancer," that explores the history of the disease that causes one quarter of all American deaths.
56 minutes
MY LIST
Acclaimed cancer physician and author of the Pulitzer Prize-winning The Emperor of All Maladies, Siddhartha Mukherjee comes to CHF to discuss his most recent work, The Gene, a magnificent history of the gene and a response to the defining question of the future: What becomes of being human when we learn to “read” and “write” our own genetic information. Mukherjee interweaves science, social history, and the story of his own family to explain the powerful science of genetics and to grapple with the extraordinary influence of heredity on our lives, personalities, identities, and fates.
Siddhartha Mukherjee: On The Gene: Unlocking the Human Code
82 minutes
MY LIST
Genetics has revolutionised not just how we think of biology but how we think of ourselves. We are, in the words of one geneticist, the first organism that has ‘learned to read its own instructions’. Now, with the breakthrough of gene-editing technology — whose precision allows us to alter a single letter of DNA — we can now not only decipher but rewrite our genetic code. We may soon be able to treat diseases such as cancer not simply with drugs, but with genetic manipulation. Yet behind this medical revolution lies the prospect of something altogether more worrying. Already, we possess the technology to add to our genetic code at will, and thus create the world’s first generation of ‘transgenic’ humans. As we intervene genetically on ourselves with ever more accuracy, do we risk changing what it means to be human? In a potential quest for the genetically ‘normal’, will we risk annihilating the very diversity and mutations on which evolution depends? <br> These are some of the questions that the Pulitzer prize-winning author, cancer geneticist and stem-cell biologist Siddhartha Mukherjee will be exploring when he comes to the Intelligence Squared stage. Joining him will be neuroscientist and BBC broadcaster Daniel Glaser, director of the Science Gallery at King’s College London and former Head of Engaging Science at the Wellcome Trust.
Andrew Lo: On Financial Engineering and Curing Cancer at TedXCambridge
20 minutes
MY LIST
We are making breakthroughs almost weekly in our understanding of cancer and other deadly diseases, both in how to treat and – in some cases – how to cure them. So why is funding for early stage biomedical research and development declining just when we need it most? One answer is that the financial risk of drug development has increased, and investors don’t like risk. What if we could reduce the risk and increase the reward through financial engineering? By applying tools like portfolio theory, securitization, and derivative securities to construct “megafunds” that invest in many biomedical projects, we can tap into the power of global financial markets to raise billions of dollars. If structured properly, investors can earn attractive returns with tolerable levels of risk, and many more patients can get the drugs they desperately need. Finance doesn’t have to be a zero-sum game; we can do well by doing good if we have sufficient scale.